董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Neal Walker | 男 | Director, President and Chief Executive Officer | 47 | 337.56万美元 | 317.53 | 2017-04-21 |
| Stephen A. Tullman | 男 | Chairman | 51 | 10.00万美元 | 未持股 | 2017-04-21 |
| Christopher Molineaux | 男 | Director | 51 | 14.20万美元 | 19.40 | 2017-04-21 |
| William Humphries | 男 | Director | 50 | 11.25万美元 | 18.95 | 2017-04-21 |
| Andrew Powell | 男 | Director | 59 | 2.04万美元 | 未持股 | 2017-04-21 |
| Anand Mehra | 男 | Director | 41 | 12.05万美元 | 85.28 | 2017-04-21 |
| Richard A. Bierly | 男 | Director | 61 | 14.15万美元 | 未持股 | 2017-04-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Neal Walker | 男 | Director, President and Chief Executive Officer | 47 | 337.56万美元 | 317.53 | 2017-04-21 |
| Christopher Powala | 男 | Chief Operating Officer | 57 | 217.60万美元 | 未持股 | 2017-04-21 |
| Stuart Shanler | 男 | Chief Scientific Officer | 56 | 229.63万美元 | 未持股 | 2017-04-21 |
| Kamil Ali Jackson | 女 | Chief Legal Officer | 58 | 272.52万美元 | 未持股 | 2017-04-21 |
| Frank Ruffo | 男 | Chief Financial Officer | 51 | 未披露 | 未持股 | 2017-04-21 |
董事简历
中英对照 | 中文 | 英文- Neal Walker
-
Neal Walker，曾在Aldeyra Therapeutics， Inc.任职。2013年6月起担任董事会成员。他是上市药物开发公司Aclaris Therapeutics， Inc.的董事会主席，此前曾担任总裁兼首席执行官（直到2022年12月）。他是董事会认证的皮肤科医生和连续企业家，在生物制药行业拥有超过25年的经验。在2012年创立Aclaris Therapeutics， Inc.之前，他曾担任Vicept Therapeutics， Inc.（被Allergan， Inc.收购）的联合创始人、总裁兼首席执行官（2009年至2012年）。他共同创立并领导了许多生命科学公司：Octagon Research Solutions， Inc.，生物制药公司的软件和服务提供商（被Accenture plc收购）；Trigenesis Therapeutics, Inc.，一家专业皮肤科公司，他曾担任首席医疗官（被Dr. Reddy's Laboratories Ltd收购）；和Cutix公司（一家商业皮肤科公司，销售PreSun，这是一个从百时美施贵宝公司收购的防晒霜品牌）。他在强生公司开始了他的制药行业职业生涯。除了Aclaris，他目前也是Zoomi， Inc.和Myota， Inc.的董事会成员。他曾担任Octagon（一家合同研究组织）的董事会成员。他也是Flexible Medical Systems LLC（一家私人持有的医疗设备公司）的顾问委员会成员。他持有The Wharton School of The University of Pennsylvania的工商管理硕士学位，Philadelphia College of Osteopathic Medicine的博士学位，以及Lehigh大学的生物学学士学位。
Neal Walker,is the Chair of the Board of Directors, and since January 2024 the interim Chief Executive Officer at Aclaris Therapeutics, Inc., a publicly traded drug development company, having previously served as President and Chief Executive Officer until December 2022. He is a board-certified dermatologist and serial entrepreneur with over 25 years of experience in the biopharmaceutical industry. Prior to founding Aclaris Therapeutics, Inc. in 2012, he was co-founder, President and CEO of Vicept Therapeutics, Inc. (acquired by Allergan, Inc.) from 2009 to 2012. Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc); Trigenesis Therapeutics, Inc., a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Ltd); and Cutix Inc., a commercial dermatology company that markets PreSun, a sunscreen brand acquired from Bristol-Myers Squibb Co. He began his pharmaceutical industry career at Johnson & Johnson, Inc. In addition to Aclaris, Dr. Walker currently is also on the Board of Directors of Zoomi, Inc, and Myota, Inc. Dr. Walker previously served on the Board of Directors for Octagon, a contract research organization. He is also on the Advisory Board of Flexible Medical Systems LLC, a privately held medical device company. Dr. Walker received his M.B.A. from The Wharton School of the University of Pennsylvania, his D.O. from Philadelphia College of Osteopathic Medicine, and a B.A. in Biology from Lehigh University. - Neal Walker，曾在Aldeyra Therapeutics， Inc.任职。2013年6月起担任董事会成员。他是上市药物开发公司Aclaris Therapeutics， Inc.的董事会主席，此前曾担任总裁兼首席执行官（直到2022年12月）。他是董事会认证的皮肤科医生和连续企业家，在生物制药行业拥有超过25年的经验。在2012年创立Aclaris Therapeutics， Inc.之前，他曾担任Vicept Therapeutics， Inc.（被Allergan， Inc.收购）的联合创始人、总裁兼首席执行官（2009年至2012年）。他共同创立并领导了许多生命科学公司：Octagon Research Solutions， Inc.，生物制药公司的软件和服务提供商（被Accenture plc收购）；Trigenesis Therapeutics, Inc.，一家专业皮肤科公司，他曾担任首席医疗官（被Dr. Reddy's Laboratories Ltd收购）；和Cutix公司（一家商业皮肤科公司，销售PreSun，这是一个从百时美施贵宝公司收购的防晒霜品牌）。他在强生公司开始了他的制药行业职业生涯。除了Aclaris，他目前也是Zoomi， Inc.和Myota， Inc.的董事会成员。他曾担任Octagon（一家合同研究组织）的董事会成员。他也是Flexible Medical Systems LLC（一家私人持有的医疗设备公司）的顾问委员会成员。他持有The Wharton School of The University of Pennsylvania的工商管理硕士学位，Philadelphia College of Osteopathic Medicine的博士学位，以及Lehigh大学的生物学学士学位。
- Neal Walker,is the Chair of the Board of Directors, and since January 2024 the interim Chief Executive Officer at Aclaris Therapeutics, Inc., a publicly traded drug development company, having previously served as President and Chief Executive Officer until December 2022. He is a board-certified dermatologist and serial entrepreneur with over 25 years of experience in the biopharmaceutical industry. Prior to founding Aclaris Therapeutics, Inc. in 2012, he was co-founder, President and CEO of Vicept Therapeutics, Inc. (acquired by Allergan, Inc.) from 2009 to 2012. Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc); Trigenesis Therapeutics, Inc., a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Ltd); and Cutix Inc., a commercial dermatology company that markets PreSun, a sunscreen brand acquired from Bristol-Myers Squibb Co. He began his pharmaceutical industry career at Johnson & Johnson, Inc. In addition to Aclaris, Dr. Walker currently is also on the Board of Directors of Zoomi, Inc, and Myota, Inc. Dr. Walker previously served on the Board of Directors for Octagon, a contract research organization. He is also on the Advisory Board of Flexible Medical Systems LLC, a privately held medical device company. Dr. Walker received his M.B.A. from The Wharton School of the University of Pennsylvania, his D.O. from Philadelphia College of Osteopathic Medicine, and a B.A. in Biology from Lehigh University.
- Stephen A. Tullman
-
Stephen A. Tullman 自2012年8月担任董事长。Tullman先生在2011年5月联合创立了NeXeption股份有限公司（NeXeption, Inc.），2012年8月创立了NeXeption有限责任公司（NeXeption, LLC）目前担任NeXeption有限责任公司（NeXeption, LLC）的经营人员。他先前担任Ceptaris Therapeutics股份有限公司（Ceptaris Therapeutics, Inc.，一家生物制药公司）的董事长、总裁和首席执行官（2011年5月-2013年9月被Actelion US Holdings公司（Actelion US Holdings Company，Actelion Ltd的子公司）收购）。Tullman先生担任Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.）的董事长（2009-2011年7月被Allergan股份有限公司（Allergan, Inc.）收购）。2005年Tullman先生联合创立了Ception Therapeutics股份有限公司（Ception Therapeutics, Inc.），也担任公司的总裁和首席执行官直到2010年被Cephalon股份有限公司（Cephalon, Inc.）收购。2003年Tullman先生联合创立了Trigenesis Therapeutics股份有限公司（Trigenesis Therapeutics, Inc.），担任商务总监，被Dr. Reddy's Laboratories 股份有限公司（Dr. Reddy's Laboratories Inc.）收购。Tullman先生在SmithKline Beecham（一家制药公司）开始他的职业生涯，他在财务、销售、营销你和研发方面担任许多职位，承担着日益重要的责任。他目前担任Alexar Therapeutics股份有限公司（Alexar Therapeutics, Inc.，一家专业皮肤病公司）董事长，也在几家其他的私人持股公司董事会工作。他拥有罗格斯大学（Rutgers University ）会计学士学位。
Stephen A. Tullman has served as Chairman of our Board since August 2012. Mr. Tullman co-founded NeXeption, Inc., a biopharmaceutical assets management company, in May 2011 and its affiliated entity NeXeption, LLC in August 2012 and currently serves as the managing member of NeXeption, LLC and certain of its affiliates. He previously served as Chairman, President and Chief Executive Officer of Ceptaris Therapeutics, Inc., a biopharmaceutical company, from May 2011 until its acquisition by Actelion US Holdings Company, a subsidiary of Actelion Ltd, in September 2013. Mr. Tullman served as Chairman of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. In 2005 Mr. Tullman co-founded Ception Therapeutics, Inc. and served as its President and Chief Executive Officer until its acquisition by Cephalon, Inc. in 2010. In 2003 Mr. Tullman co-founded Trigenesis Therapeutics, Inc., where he served as its Chief Business Officer acquired by Dr. Reddy's Laboratories Inc. Mr. Tullman began his career at SmithKline Beecham, a pharmaceutical company, where he held positions of increasing responsibility in finance, sales, marketing, and research and development. Mr. Tullman currently serves as the chairman of the board of directors of Ralexar Therapeutics, Inc., a specialty dermatology company, and on the boards of directors of several other privately held companies. Mr. Tullman received a B.S. degree in Accounting from Rutgers University. - Stephen A. Tullman 自2012年8月担任董事长。Tullman先生在2011年5月联合创立了NeXeption股份有限公司（NeXeption, Inc.），2012年8月创立了NeXeption有限责任公司（NeXeption, LLC）目前担任NeXeption有限责任公司（NeXeption, LLC）的经营人员。他先前担任Ceptaris Therapeutics股份有限公司（Ceptaris Therapeutics, Inc.，一家生物制药公司）的董事长、总裁和首席执行官（2011年5月-2013年9月被Actelion US Holdings公司（Actelion US Holdings Company，Actelion Ltd的子公司）收购）。Tullman先生担任Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.）的董事长（2009-2011年7月被Allergan股份有限公司（Allergan, Inc.）收购）。2005年Tullman先生联合创立了Ception Therapeutics股份有限公司（Ception Therapeutics, Inc.），也担任公司的总裁和首席执行官直到2010年被Cephalon股份有限公司（Cephalon, Inc.）收购。2003年Tullman先生联合创立了Trigenesis Therapeutics股份有限公司（Trigenesis Therapeutics, Inc.），担任商务总监，被Dr. Reddy's Laboratories 股份有限公司（Dr. Reddy's Laboratories Inc.）收购。Tullman先生在SmithKline Beecham（一家制药公司）开始他的职业生涯，他在财务、销售、营销你和研发方面担任许多职位，承担着日益重要的责任。他目前担任Alexar Therapeutics股份有限公司（Alexar Therapeutics, Inc.，一家专业皮肤病公司）董事长，也在几家其他的私人持股公司董事会工作。他拥有罗格斯大学（Rutgers University ）会计学士学位。
- Stephen A. Tullman has served as Chairman of our Board since August 2012. Mr. Tullman co-founded NeXeption, Inc., a biopharmaceutical assets management company, in May 2011 and its affiliated entity NeXeption, LLC in August 2012 and currently serves as the managing member of NeXeption, LLC and certain of its affiliates. He previously served as Chairman, President and Chief Executive Officer of Ceptaris Therapeutics, Inc., a biopharmaceutical company, from May 2011 until its acquisition by Actelion US Holdings Company, a subsidiary of Actelion Ltd, in September 2013. Mr. Tullman served as Chairman of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. In 2005 Mr. Tullman co-founded Ception Therapeutics, Inc. and served as its President and Chief Executive Officer until its acquisition by Cephalon, Inc. in 2010. In 2003 Mr. Tullman co-founded Trigenesis Therapeutics, Inc., where he served as its Chief Business Officer acquired by Dr. Reddy's Laboratories Inc. Mr. Tullman began his career at SmithKline Beecham, a pharmaceutical company, where he held positions of increasing responsibility in finance, sales, marketing, and research and development. Mr. Tullman currently serves as the chairman of the board of directors of Ralexar Therapeutics, Inc., a specialty dermatology company, and on the boards of directors of several other privately held companies. Mr. Tullman received a B.S. degree in Accounting from Rutgers University.
- Christopher Molineaux
-
Christopher Molineaux自2014年1月担任公司的董事会成员。2009年起他在Pennsylvania BIO（一家制药和生物行业宣传组织）担任总裁和首席执行官。在加入Pennsylvania BIO之前，他担任Johnson & Johnson制药通讯和公共事务全球副总裁。他先前担任制药研发协会（Pharmaceutical Research and Manufacturers Association）的公共事务副总裁。他拥有圣十字学院（College of the Holy Cross）学士学位。
Christopher Molineaux has served as a member of Board since January 2014. Since 2009 Mr. Molineaux has served as President and Chief Executive Officer of Life Sciences Pennsylvania, formerly Pennsylvania Bio, a pharmaceutical and biotech industry advocacy organization. Prior to joining Life Sciences Pennsylvania, Mr. Molineaux served as worldwide Vice President of pharmaceutical communication and public affairs for Johnson & Johnson. Mr. Molineaux previously served as Vice President for Public Affairs at the Pharmaceutical Research and Manufacturers Association. He holds a B.A. degree from the College of the Holy Cross. - Christopher Molineaux自2014年1月担任公司的董事会成员。2009年起他在Pennsylvania BIO（一家制药和生物行业宣传组织）担任总裁和首席执行官。在加入Pennsylvania BIO之前，他担任Johnson & Johnson制药通讯和公共事务全球副总裁。他先前担任制药研发协会（Pharmaceutical Research and Manufacturers Association）的公共事务副总裁。他拥有圣十字学院（College of the Holy Cross）学士学位。
- Christopher Molineaux has served as a member of Board since January 2014. Since 2009 Mr. Molineaux has served as President and Chief Executive Officer of Life Sciences Pennsylvania, formerly Pennsylvania Bio, a pharmaceutical and biotech industry advocacy organization. Prior to joining Life Sciences Pennsylvania, Mr. Molineaux served as worldwide Vice President of pharmaceutical communication and public affairs for Johnson & Johnson. Mr. Molineaux previously served as Vice President for Public Affairs at the Pharmaceutical Research and Manufacturers Association. He holds a B.A. degree from the College of the Holy Cross.
- William Humphries
-
William Humphries于2021年4月12日被任命为董事会成员。汉弗莱斯先生于2021年5月加入生物技术公司Isosceles Pharmaceuticals Inc.，并担任其首席执行官。2018年8月至2020年12月，Humphries先生担任Bausch Health Companies Inc.骨科皮肤科总裁兼集团公司董事长，此前曾于2017年1月至2018年8月担任皮肤科执行副总裁、公司集团董事长。2012年至2016年12月，他担任Merz，Inc.北美业务的总裁兼首席执行官，该公司是专业医疗保健公司Merz Pharma Group的附属公司。从2004年到2012年，他曾在皮肤科制药公司Stiefel Laboratories，Inc.担任多个领导职务，包括担任首席商务官，然后从2008年开始担任总裁。Stiefel于2009年被葛兰素史克收购。收购完成后，亨弗里斯先生在2009年至2012年期间担任GSK旗下公司Stiefel的皮肤科总裁。在加入Stiefel之前，Humphries先生曾在眼力健制药公司的销售和营销、业务发展以及国际营销方面担任行政职务，最后担任其美国护肤品业务副总裁。Humphries先生目前在上市制药公司Aclaris Therapeutics, Inc.的董事会任职，自2016年以来一直担任该职位，在上市生物制药公司Clearside Medical，Inc.的董事会任职，自2012年以来一直担任该职位。自2018年2月起担任Clearside Medical，Inc.董事会主席。曾获巴克内尔大学文学士、佩珀代因大学工商管理硕士学位。亨弗里斯还担任北卡罗来纳州立大学全球奢侈品管理项目的行业顾问委员会成员。
William Humphries was appointed to the Board on April 12 2021. Mr. Humphries joined Isosceles Pharmaceuticals Inc., a biotechnology company, in May 2021 and serves as its Chief Executive Officer. From August 2018 until December 2020 Mr. Humphries served as President and Group Company Chairman, Ortho Dermatologics of Bausch Health Companies Inc., where he previously served as Executive Vice President, Company Group Chairman, Dermatology from January 2017 to August 2018. From 2012 to December 2016 he served as President and Chief Executive Officer of the North American business of Merz, Inc., an affiliate of Merz Pharma Group, a specialty healthcare company. From 2004 to 2012 he served in a number of leadership positions with Stiefel Laboratories, Inc., a dermatology pharmaceutical company, including as its Chief Commercial Officer and then as its President beginning in 2008. Stiefel was acquired by GlaxoSmithKline in 2009. After the acquisition, Mr. Humphries served as the President of Dermatology for Stiefel, a GSK Company from 2009 until 2012. Before Stiefel, Mr. Humphries served in executive roles in sales and marketing, business development, and international marketing for Allergan, Inc., concluding as vice president of its U.S. skincare business. Mr. Humphries currently serves on the board of directors of Aclaris Therapeutics, Inc., a publicly traded pharmaceutical company, a position he has held since 2016 and Clearside Medical, Inc., a publicly traded biopharmaceutical company, a position he has held since 2012. He has served as chairman of the board of directors of Clearside Medical, Inc. since February 2018. He received a Bachelor of Arts from Bucknell University and a Master of Business Administration from Pepperdine University. Mr. Humphries also serves on the industry advisory board for the Global Luxury Management Program at North Carolina State University. - William Humphries于2021年4月12日被任命为董事会成员。汉弗莱斯先生于2021年5月加入生物技术公司Isosceles Pharmaceuticals Inc.，并担任其首席执行官。2018年8月至2020年12月，Humphries先生担任Bausch Health Companies Inc.骨科皮肤科总裁兼集团公司董事长，此前曾于2017年1月至2018年8月担任皮肤科执行副总裁、公司集团董事长。2012年至2016年12月，他担任Merz，Inc.北美业务的总裁兼首席执行官，该公司是专业医疗保健公司Merz Pharma Group的附属公司。从2004年到2012年，他曾在皮肤科制药公司Stiefel Laboratories，Inc.担任多个领导职务，包括担任首席商务官，然后从2008年开始担任总裁。Stiefel于2009年被葛兰素史克收购。收购完成后，亨弗里斯先生在2009年至2012年期间担任GSK旗下公司Stiefel的皮肤科总裁。在加入Stiefel之前，Humphries先生曾在眼力健制药公司的销售和营销、业务发展以及国际营销方面担任行政职务，最后担任其美国护肤品业务副总裁。Humphries先生目前在上市制药公司Aclaris Therapeutics, Inc.的董事会任职，自2016年以来一直担任该职位，在上市生物制药公司Clearside Medical，Inc.的董事会任职，自2012年以来一直担任该职位。自2018年2月起担任Clearside Medical，Inc.董事会主席。曾获巴克内尔大学文学士、佩珀代因大学工商管理硕士学位。亨弗里斯还担任北卡罗来纳州立大学全球奢侈品管理项目的行业顾问委员会成员。
- William Humphries was appointed to the Board on April 12 2021. Mr. Humphries joined Isosceles Pharmaceuticals Inc., a biotechnology company, in May 2021 and serves as its Chief Executive Officer. From August 2018 until December 2020 Mr. Humphries served as President and Group Company Chairman, Ortho Dermatologics of Bausch Health Companies Inc., where he previously served as Executive Vice President, Company Group Chairman, Dermatology from January 2017 to August 2018. From 2012 to December 2016 he served as President and Chief Executive Officer of the North American business of Merz, Inc., an affiliate of Merz Pharma Group, a specialty healthcare company. From 2004 to 2012 he served in a number of leadership positions with Stiefel Laboratories, Inc., a dermatology pharmaceutical company, including as its Chief Commercial Officer and then as its President beginning in 2008. Stiefel was acquired by GlaxoSmithKline in 2009. After the acquisition, Mr. Humphries served as the President of Dermatology for Stiefel, a GSK Company from 2009 until 2012. Before Stiefel, Mr. Humphries served in executive roles in sales and marketing, business development, and international marketing for Allergan, Inc., concluding as vice president of its U.S. skincare business. Mr. Humphries currently serves on the board of directors of Aclaris Therapeutics, Inc., a publicly traded pharmaceutical company, a position he has held since 2016 and Clearside Medical, Inc., a publicly traded biopharmaceutical company, a position he has held since 2012. He has served as chairman of the board of directors of Clearside Medical, Inc. since February 2018. He received a Bachelor of Arts from Bucknell University and a Master of Business Administration from Pepperdine University. Mr. Humphries also serves on the industry advisory board for the Global Luxury Management Program at North Carolina State University.
- Andrew Powell
-
Andrew Powell，Esq，他自2013年9月起担任InterMune的执行副总裁，法律总顾问以及公司秘书。他最近担任Cornerstone Therapeutics自2009年11月起止2013年8月的执行副总裁，法律总顾问及秘书。先前自2008年7月至2009年1月他在ImClone Systems担任高级副总裁兼法律总顾问，而自2004年9月至2008年6月则在皮肤病学公司Collagenex Pharmaceuticals作为法律总顾问。先前自1989年至2004年8月他在医疗保险公司Baxter担任各种职位。他持有一个来自Chapel Hill的University of North Carolina的文学士学位，以及一个来自Stanford Law School的法学博士学位。
Andrew Powell has served as a member of the Board of Directors since October 2018. Mr. Powell is currently an independent advisor to small and mid-size companies and research institutions in the life sciences sector. He serves on the Board of Directors of Aclaris Therapeutics, Inc. NASDAQ:ACRS, a clinical stage biopharmaceutical company, since 2017 where he is a member of the Audit and the Nominating and Governance Committees. He also serves on the Board of Directors of Silverback Therapeutics, Inc. (NASDAQ:SBTX), a biopharmaceutical company developing tissue targeted therapies designed to result in life changing outcomes, since 2020 where he is chairman of the Compensation Committee. He has served on the Board of Directors of Synthorx, Inc., a biotechnology company, from December 2018 until January 2020 when that company was acquired by Sanofi-Aventis. He served as Senior Vice President, General Counsel, and Corporate Secretary of Medivation, Inc. from May 2015 until November 2016 when the company was acquired by Pfizer, Inc. Mr. Powell served as Executive Vice President, General Counsel, and Corporate Secretary of InterMune, Inc. from September 2013 to March 2015 when the company was acquired by Roche, Inc. From 2005 to 2013 he served as an executive in various development stage and commercially focused biotechnology companies, including ImClone Systems, Inc., prior to its acquisition by Lilly, Inc. Earlier in his career, Mr. Powell held positions of increasing responsibility for nearly 15 years at the multi-national healthcare and medical solutions company Baxter International, Inc., where he was instrumental in a series of transactions that established Baxter throughout Eastern Europe, Asia and Latin America. Mr. Powell holds a Bachelor of Arts degree from the University of North Carolina at Chapel Hill and a Juris Doctorate from Stanford Law School. - Andrew Powell，Esq，他自2013年9月起担任InterMune的执行副总裁，法律总顾问以及公司秘书。他最近担任Cornerstone Therapeutics自2009年11月起止2013年8月的执行副总裁，法律总顾问及秘书。先前自2008年7月至2009年1月他在ImClone Systems担任高级副总裁兼法律总顾问，而自2004年9月至2008年6月则在皮肤病学公司Collagenex Pharmaceuticals作为法律总顾问。先前自1989年至2004年8月他在医疗保险公司Baxter担任各种职位。他持有一个来自Chapel Hill的University of North Carolina的文学士学位，以及一个来自Stanford Law School的法学博士学位。
- Andrew Powell has served as a member of the Board of Directors since October 2018. Mr. Powell is currently an independent advisor to small and mid-size companies and research institutions in the life sciences sector. He serves on the Board of Directors of Aclaris Therapeutics, Inc. NASDAQ:ACRS, a clinical stage biopharmaceutical company, since 2017 where he is a member of the Audit and the Nominating and Governance Committees. He also serves on the Board of Directors of Silverback Therapeutics, Inc. (NASDAQ:SBTX), a biopharmaceutical company developing tissue targeted therapies designed to result in life changing outcomes, since 2020 where he is chairman of the Compensation Committee. He has served on the Board of Directors of Synthorx, Inc., a biotechnology company, from December 2018 until January 2020 when that company was acquired by Sanofi-Aventis. He served as Senior Vice President, General Counsel, and Corporate Secretary of Medivation, Inc. from May 2015 until November 2016 when the company was acquired by Pfizer, Inc. Mr. Powell served as Executive Vice President, General Counsel, and Corporate Secretary of InterMune, Inc. from September 2013 to March 2015 when the company was acquired by Roche, Inc. From 2005 to 2013 he served as an executive in various development stage and commercially focused biotechnology companies, including ImClone Systems, Inc., prior to its acquisition by Lilly, Inc. Earlier in his career, Mr. Powell held positions of increasing responsibility for nearly 15 years at the multi-national healthcare and medical solutions company Baxter International, Inc., where he was instrumental in a series of transactions that established Baxter throughout Eastern Europe, Asia and Latin America. Mr. Powell holds a Bachelor of Arts degree from the University of North Carolina at Chapel Hill and a Juris Doctorate from Stanford Law School.
- Anand Mehra
-
Anand Mehra, M.D.，自2007年10月以来，在本公司的董事会任职。他目前在一家专注于生物技术投资的风险投资公司- Sofinnova Ventures担任一般合伙人，他是于2007年加入该公司并担任负责人的，负责生物技术投资业务。在Sofinnova之前，他曾在JPMorgan Chase公司的私人股本和风险资本部工作。在加入风险资本圈之前，他曾在McKinsey公司的医药部担任顾问，对医药和生物技术关键战略问题提出建议。他目前在Aerie Pharmaceuticals股份有限公司以及一些私营公司的董事会任职。Mehra博士是在哥伦比亚（Columbia）大学内科和外科医师学院获得他的医学博士学位，以及从Virginia大学（他是该校的一位Echols学者）的美国大学优等生荣誉学会毕业的。
Anand Mehra has served on Board since May 2014. Dr. Mehra currently is a General Partner of Sofinnova Ventures, which he joined in May 2007. Prior to joining Sofinnova Ventures, Dr. Mehra worked in J.P. Morgan's private equity and venture capital group and, before that, Dr. Mehra was a consultant in McKinsey & Company's pharmaceutical practice. Dr. Mehra previously has served on the board of directors of Aerie Pharmaceuticals and Marinus Pharmaceuticals. He currently serves on the board of Aclaris Therapeutics, Inc. and Merus N.V., positions he has held since 2013 and 2015 respectively, as well as several private companies. Dr. Mehra holds a B.A. from the University of Virginia and an M.D. from Columbia University's College of Physicians and Surgeons. - Anand Mehra, M.D.，自2007年10月以来，在本公司的董事会任职。他目前在一家专注于生物技术投资的风险投资公司- Sofinnova Ventures担任一般合伙人，他是于2007年加入该公司并担任负责人的，负责生物技术投资业务。在Sofinnova之前，他曾在JPMorgan Chase公司的私人股本和风险资本部工作。在加入风险资本圈之前，他曾在McKinsey公司的医药部担任顾问，对医药和生物技术关键战略问题提出建议。他目前在Aerie Pharmaceuticals股份有限公司以及一些私营公司的董事会任职。Mehra博士是在哥伦比亚（Columbia）大学内科和外科医师学院获得他的医学博士学位，以及从Virginia大学（他是该校的一位Echols学者）的美国大学优等生荣誉学会毕业的。
- Anand Mehra has served on Board since May 2014. Dr. Mehra currently is a General Partner of Sofinnova Ventures, which he joined in May 2007. Prior to joining Sofinnova Ventures, Dr. Mehra worked in J.P. Morgan's private equity and venture capital group and, before that, Dr. Mehra was a consultant in McKinsey & Company's pharmaceutical practice. Dr. Mehra previously has served on the board of directors of Aerie Pharmaceuticals and Marinus Pharmaceuticals. He currently serves on the board of Aclaris Therapeutics, Inc. and Merus N.V., positions he has held since 2013 and 2015 respectively, as well as several private companies. Dr. Mehra holds a B.A. from the University of Virginia and an M.D. from Columbia University's College of Physicians and Surgeons.
- Richard A. Bierly
-
Richard A. Bierly，他与2014年加入我公司担任首席财务官。他将自己在Glaxo-SmithKline, Aventis, Centocor, Inc.和强生（Johnson & Johnson）公司任职的30年经验带到了Medivation。从2013年至2014年3月，他担任Ernst & Young LLP财务会计咨询服务业务执行董事，该业务对象为生命科学及其他客户，提供财政职务转换相关的咨询服务。从1999年至2012年他多次担任强生（Johnson & Johnson）公司高位如2010至2012年任全球财政服务副总裁，负责为强生基于美国的执行公司提供财政会计服务的新泽西共享服务中心；从2001年8月至2008年2月，他担任Centocor Inc.财政副总裁，从2006年5月起担任Ortho Biotech LP财政副总裁。从1999年10月至2001年8月，他担任Centocor, Inc.财政执行董事跟进强生（Johnson & Johnson）收购Centocor事项。从1997年至1998年，他担任Centocor Diagnostics, Inc.副总裁和首席财政官，1998年至1999年间在Centocor被收购前担任财政执行董事。从1995年到1997年，他担任Aventis和Hoechst合资公司副总裁和财政长，该公司主营血浆业务。他于1991至1995年在Aventis，于1981至1991年在SmithKline Beecham担任过董事、对外报告和其他财政职务。他在Ernst & Young LLP开始他的公众会计师生涯。他从宾夕法尼亚州立大学（Pennsylvania State University）获得商务管理学士学位，有注册的宾夕法尼亚和新泽西公众会计师证。
Richard A. Bierly has served as a member of our Board since October 2015. From March 2014 until April 2016 Mr. Bierly served as the chief financial officer of Medivation, Inc., a publicly traded biopharmaceutical company. Mr. Bierly retired from Medivation in July 2016 after which he remained a consultant until September 2016. Mr. Bierly served as an executive director in Ernst & Young LLP's Financial Accounting Advisory Services practice for life sciences and other clients from September 2013 to March 2014 where he provided advisory services in connection with finance function transformations. From 1999 to 2012 he served in several leadership roles at Johnson & Johnson, including from August 2010 to 2012 as vice president, global finance services, where he was responsible for a New Jersey-based shared services center providing financial accounting services to Johnson & Johnson’s U.S.-based operating companies. At Johnson & Johnson, Mr. Bierly also served as vice president, finance of Centocor, Inc., and as vice president, finance, of Ortho Biotech LP, both subsidiaries of Johnson & Johnson. Mr. Bierly received his Bachelor of Business Administration degree from Pennsylvania State University and is a certified public accountant in Pennsylvania inactive and New Jersey (inactive). Mr. Bierly currently serves on board of directors of Impax Laboratories, Inc., a publicly held specialty pharmaceutical company. - Richard A. Bierly，他与2014年加入我公司担任首席财务官。他将自己在Glaxo-SmithKline, Aventis, Centocor, Inc.和强生（Johnson & Johnson）公司任职的30年经验带到了Medivation。从2013年至2014年3月，他担任Ernst & Young LLP财务会计咨询服务业务执行董事，该业务对象为生命科学及其他客户，提供财政职务转换相关的咨询服务。从1999年至2012年他多次担任强生（Johnson & Johnson）公司高位如2010至2012年任全球财政服务副总裁，负责为强生基于美国的执行公司提供财政会计服务的新泽西共享服务中心；从2001年8月至2008年2月，他担任Centocor Inc.财政副总裁，从2006年5月起担任Ortho Biotech LP财政副总裁。从1999年10月至2001年8月，他担任Centocor, Inc.财政执行董事跟进强生（Johnson & Johnson）收购Centocor事项。从1997年至1998年，他担任Centocor Diagnostics, Inc.副总裁和首席财政官，1998年至1999年间在Centocor被收购前担任财政执行董事。从1995年到1997年，他担任Aventis和Hoechst合资公司副总裁和财政长，该公司主营血浆业务。他于1991至1995年在Aventis，于1981至1991年在SmithKline Beecham担任过董事、对外报告和其他财政职务。他在Ernst & Young LLP开始他的公众会计师生涯。他从宾夕法尼亚州立大学（Pennsylvania State University）获得商务管理学士学位，有注册的宾夕法尼亚和新泽西公众会计师证。
- Richard A. Bierly has served as a member of our Board since October 2015. From March 2014 until April 2016 Mr. Bierly served as the chief financial officer of Medivation, Inc., a publicly traded biopharmaceutical company. Mr. Bierly retired from Medivation in July 2016 after which he remained a consultant until September 2016. Mr. Bierly served as an executive director in Ernst & Young LLP's Financial Accounting Advisory Services practice for life sciences and other clients from September 2013 to March 2014 where he provided advisory services in connection with finance function transformations. From 1999 to 2012 he served in several leadership roles at Johnson & Johnson, including from August 2010 to 2012 as vice president, global finance services, where he was responsible for a New Jersey-based shared services center providing financial accounting services to Johnson & Johnson’s U.S.-based operating companies. At Johnson & Johnson, Mr. Bierly also served as vice president, finance of Centocor, Inc., and as vice president, finance, of Ortho Biotech LP, both subsidiaries of Johnson & Johnson. Mr. Bierly received his Bachelor of Business Administration degree from Pennsylvania State University and is a certified public accountant in Pennsylvania inactive and New Jersey (inactive). Mr. Bierly currently serves on board of directors of Impax Laboratories, Inc., a publicly held specialty pharmaceutical company.
高管简历
中英对照 | 中文 | 英文- Neal Walker
Neal Walker，曾在Aldeyra Therapeutics， Inc.任职。2013年6月起担任董事会成员。他是上市药物开发公司Aclaris Therapeutics， Inc.的董事会主席，此前曾担任总裁兼首席执行官（直到2022年12月）。他是董事会认证的皮肤科医生和连续企业家，在生物制药行业拥有超过25年的经验。在2012年创立Aclaris Therapeutics， Inc.之前，他曾担任Vicept Therapeutics， Inc.（被Allergan， Inc.收购）的联合创始人、总裁兼首席执行官（2009年至2012年）。他共同创立并领导了许多生命科学公司：Octagon Research Solutions， Inc.，生物制药公司的软件和服务提供商（被Accenture plc收购）；Trigenesis Therapeutics, Inc.，一家专业皮肤科公司，他曾担任首席医疗官（被Dr. Reddy's Laboratories Ltd收购）；和Cutix公司（一家商业皮肤科公司，销售PreSun，这是一个从百时美施贵宝公司收购的防晒霜品牌）。他在强生公司开始了他的制药行业职业生涯。除了Aclaris，他目前也是Zoomi， Inc.和Myota， Inc.的董事会成员。他曾担任Octagon（一家合同研究组织）的董事会成员。他也是Flexible Medical Systems LLC（一家私人持有的医疗设备公司）的顾问委员会成员。他持有The Wharton School of The University of Pennsylvania的工商管理硕士学位，Philadelphia College of Osteopathic Medicine的博士学位，以及Lehigh大学的生物学学士学位。
Neal Walker,is the Chair of the Board of Directors, and since January 2024 the interim Chief Executive Officer at Aclaris Therapeutics, Inc., a publicly traded drug development company, having previously served as President and Chief Executive Officer until December 2022. He is a board-certified dermatologist and serial entrepreneur with over 25 years of experience in the biopharmaceutical industry. Prior to founding Aclaris Therapeutics, Inc. in 2012, he was co-founder, President and CEO of Vicept Therapeutics, Inc. (acquired by Allergan, Inc.) from 2009 to 2012. Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc); Trigenesis Therapeutics, Inc., a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Ltd); and Cutix Inc., a commercial dermatology company that markets PreSun, a sunscreen brand acquired from Bristol-Myers Squibb Co. He began his pharmaceutical industry career at Johnson & Johnson, Inc. In addition to Aclaris, Dr. Walker currently is also on the Board of Directors of Zoomi, Inc, and Myota, Inc. Dr. Walker previously served on the Board of Directors for Octagon, a contract research organization. He is also on the Advisory Board of Flexible Medical Systems LLC, a privately held medical device company. Dr. Walker received his M.B.A. from The Wharton School of the University of Pennsylvania, his D.O. from Philadelphia College of Osteopathic Medicine, and a B.A. in Biology from Lehigh University.- Neal Walker，曾在Aldeyra Therapeutics， Inc.任职。2013年6月起担任董事会成员。他是上市药物开发公司Aclaris Therapeutics， Inc.的董事会主席，此前曾担任总裁兼首席执行官（直到2022年12月）。他是董事会认证的皮肤科医生和连续企业家，在生物制药行业拥有超过25年的经验。在2012年创立Aclaris Therapeutics， Inc.之前，他曾担任Vicept Therapeutics， Inc.（被Allergan， Inc.收购）的联合创始人、总裁兼首席执行官（2009年至2012年）。他共同创立并领导了许多生命科学公司：Octagon Research Solutions， Inc.，生物制药公司的软件和服务提供商（被Accenture plc收购）；Trigenesis Therapeutics, Inc.，一家专业皮肤科公司，他曾担任首席医疗官（被Dr. Reddy's Laboratories Ltd收购）；和Cutix公司（一家商业皮肤科公司，销售PreSun，这是一个从百时美施贵宝公司收购的防晒霜品牌）。他在强生公司开始了他的制药行业职业生涯。除了Aclaris，他目前也是Zoomi， Inc.和Myota， Inc.的董事会成员。他曾担任Octagon（一家合同研究组织）的董事会成员。他也是Flexible Medical Systems LLC（一家私人持有的医疗设备公司）的顾问委员会成员。他持有The Wharton School of The University of Pennsylvania的工商管理硕士学位，Philadelphia College of Osteopathic Medicine的博士学位，以及Lehigh大学的生物学学士学位。
- Neal Walker,is the Chair of the Board of Directors, and since January 2024 the interim Chief Executive Officer at Aclaris Therapeutics, Inc., a publicly traded drug development company, having previously served as President and Chief Executive Officer until December 2022. He is a board-certified dermatologist and serial entrepreneur with over 25 years of experience in the biopharmaceutical industry. Prior to founding Aclaris Therapeutics, Inc. in 2012, he was co-founder, President and CEO of Vicept Therapeutics, Inc. (acquired by Allergan, Inc.) from 2009 to 2012. Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc); Trigenesis Therapeutics, Inc., a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Ltd); and Cutix Inc., a commercial dermatology company that markets PreSun, a sunscreen brand acquired from Bristol-Myers Squibb Co. He began his pharmaceutical industry career at Johnson & Johnson, Inc. In addition to Aclaris, Dr. Walker currently is also on the Board of Directors of Zoomi, Inc, and Myota, Inc. Dr. Walker previously served on the Board of Directors for Octagon, a contract research organization. He is also on the Advisory Board of Flexible Medical Systems LLC, a privately held medical device company. Dr. Walker received his M.B.A. from The Wharton School of the University of Pennsylvania, his D.O. from Philadelphia College of Osteopathic Medicine, and a B.A. in Biology from Lehigh University.
- Christopher Powala
Christopher Powala联合创立了公司并于2012年7月公司成立起担任公司的运营总监。2011年7月-2012年7月，Powala先生在许多制药公司担任顾问。他联合创立了Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.）并担任运营总监（2009年-2011年7月收购Allergan股份有限公司（Allergan, Inc.））。在加入Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.）之前，他担任Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.，以埃及生物技术公司）的临床操作和全球常规事务的副总裁（2008-2009年）1993-2008年Powala先生在CollaGenex Pharmaceuticals股份有限公司（CollaGenex Pharmaceuticals, Inc，一家皮肤科专业制药公司）工作，担任药物研发和常规事务副总裁。先前，他也在Wyeth Laboratories股份有限公司（Wyeth Laboratories, Inc.）的产品开发和常规事务担任不同的工作。他拥有纽约州立大学摄政学院（State University of New York-Regents College）生物学士学位。
Christopher Powala co-founded our company and has served as our Chief Operating Officer since our inception in July 2012. Since January 2014 Mr. Powala has served part-time as a regulatory consultant at Ralexar Therapeutics, Inc., a specialty dermatology company. Between July 2011 and July 2012 Mr. Powala served as a consultant to a number of pharmaceutical companies. Mr. Powala co-founded and served as Chief Operating Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Prior to joining Vicept Therapeutics, Inc., from 2008 to 2009 he served as Vice President, Clinical Operations & Global Regulatory Affairs for Vital Therapies, Inc., a biotechnology company. From 1993 to 2008 Mr. Powala was with CollaGenex Pharmaceuticals, Inc, a dermatology-focused specialty pharmaceutical company, where he served as Vice President, Drug Development and Regulatory Affairs. Previously, Mr. Powala also held various positions in product development and regulatory affairs at Wyeth Laboratories, Inc. Mr. Powala received his bachelor's degree in Biology from State University of New York-Regents College.- Christopher Powala联合创立了公司并于2012年7月公司成立起担任公司的运营总监。2011年7月-2012年7月，Powala先生在许多制药公司担任顾问。他联合创立了Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.）并担任运营总监（2009年-2011年7月收购Allergan股份有限公司（Allergan, Inc.））。在加入Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.）之前，他担任Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.，以埃及生物技术公司）的临床操作和全球常规事务的副总裁（2008-2009年）1993-2008年Powala先生在CollaGenex Pharmaceuticals股份有限公司（CollaGenex Pharmaceuticals, Inc，一家皮肤科专业制药公司）工作，担任药物研发和常规事务副总裁。先前，他也在Wyeth Laboratories股份有限公司（Wyeth Laboratories, Inc.）的产品开发和常规事务担任不同的工作。他拥有纽约州立大学摄政学院（State University of New York-Regents College）生物学士学位。
- Christopher Powala co-founded our company and has served as our Chief Operating Officer since our inception in July 2012. Since January 2014 Mr. Powala has served part-time as a regulatory consultant at Ralexar Therapeutics, Inc., a specialty dermatology company. Between July 2011 and July 2012 Mr. Powala served as a consultant to a number of pharmaceutical companies. Mr. Powala co-founded and served as Chief Operating Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Prior to joining Vicept Therapeutics, Inc., from 2008 to 2009 he served as Vice President, Clinical Operations & Global Regulatory Affairs for Vital Therapies, Inc., a biotechnology company. From 1993 to 2008 Mr. Powala was with CollaGenex Pharmaceuticals, Inc, a dermatology-focused specialty pharmaceutical company, where he served as Vice President, Drug Development and Regulatory Affairs. Previously, Mr. Powala also held various positions in product development and regulatory affairs at Wyeth Laboratories, Inc. Mr. Powala received his bachelor's degree in Biology from State University of New York-Regents College.
- Stuart Shanler
Stuart Shanler在2012年7月联合创立公司并于2012年7月公司成立起担任公司的首席科学家。在2011年7月-2012年7月，Shanler博士在许多制药公司担任顾问。他联合发明了一种局部红斑痤疮的药物，并联合创立了Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.）并担任首席科学家（2009-2011年7月收购Allergan股份有限公司（Allergan, Inc.））。先前，Shanler博士是私人执业的皮肤外科医生。他是委员会认证的皮肤科医生，拥有奥尔巴尼协和大学医学院（Albany Medical College of Union University）硕士学位和宾夕法尼亚大学（University of Pennsylvania）生物行为基础和生物学士学位。
Stuart Shanler, M.D. co-founded our company and has served as our Chief Scientific Officer since our inception in July 2012. Since January 2014 Dr. Shanler has served part-time as a medical and clinical development consultant at Ralexar Therapeutics, Inc., a specialty dermatology company. Between July 2011 and July 2012 Dr. Shanler served as a consultant to a number of pharmaceutical companies. Dr. Shanler co-invented a topical rosacea drug for, and co-founded and served as Chief Scientific Officer of, Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Shanler was a dermatologic surgeon in private practice. Dr. Shanler is a board-certified dermatologist and received his M.D. degree from Albany Medical College of Union University and received B.S. degrees in Biology and the Biological Basis of Behavior from the University of Pennsylvania.- Stuart Shanler在2012年7月联合创立公司并于2012年7月公司成立起担任公司的首席科学家。在2011年7月-2012年7月，Shanler博士在许多制药公司担任顾问。他联合发明了一种局部红斑痤疮的药物，并联合创立了Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.）并担任首席科学家（2009-2011年7月收购Allergan股份有限公司（Allergan, Inc.））。先前，Shanler博士是私人执业的皮肤外科医生。他是委员会认证的皮肤科医生，拥有奥尔巴尼协和大学医学院（Albany Medical College of Union University）硕士学位和宾夕法尼亚大学（University of Pennsylvania）生物行为基础和生物学士学位。
- Stuart Shanler, M.D. co-founded our company and has served as our Chief Scientific Officer since our inception in July 2012. Since January 2014 Dr. Shanler has served part-time as a medical and clinical development consultant at Ralexar Therapeutics, Inc., a specialty dermatology company. Between July 2011 and July 2012 Dr. Shanler served as a consultant to a number of pharmaceutical companies. Dr. Shanler co-invented a topical rosacea drug for, and co-founded and served as Chief Scientific Officer of, Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Shanler was a dermatologic surgeon in private practice. Dr. Shanler is a board-certified dermatologist and received his M.D. degree from Albany Medical College of Union University and received B.S. degrees in Biology and the Biological Basis of Behavior from the University of Pennsylvania.
- Kamil Ali Jackson
Kamil Ali Jackson联合创立了公司并于2012年7月公司成立起担任法律总监和助理秘书。另外，2011年5月Ali-Jackson女士担任NeXeption股份有限公司（NeXeption, Inc.）的法律总监（2014年1月）。2011年5月-2013年9月Ali-Jackson女士担任Ceptaris Therapeutics股份有限公司（Ceptaris Therapeutics, Inc.，一家生物技术公司）法律总监、首席合规官和秘书。2010年10月-2011年9月她是一家私人特别制药公司的顾问。2006-2010年5月她担任Ception Therapeutics股份有限公司（Ception Therapeutics, Inc.，一家商务技术公司，被Cephalon股份有限公司（Cephalon, Inc.）收购）总法律顾问和公司秘书。先前，Ali-Jackson女士担任许多制药公司的法律顾问和特许业务执行，包括Merck & Co.股份有限公司（Merck & Co., Inc.）、Dr. Reddy's Laboratories股份有限公司（Dr. Reddy's Laboratories Inc.）和Endo Pharmaceuticals股份有限公司（Endo Pharmaceuticals, Inc）。Ali-Jackson女士拥有哈佛法学院（Harvard Law School）法律博士学位和普林斯顿大学（Princeton University）政治学士学位。
Kamil Ali Jackson has served on the Board since February 2020. Ms. Ali Jackson has four decades of life sciences industry experience with public and private specialty pharmaceutical, biotech, and biopharmaceutical companies to PDS Biotech. Ms. Ali Jackson has extensive domestic and international experience with strategic alliances, drug development and commercialization collaborations, and M & A transactions. Ms. Ali Jackson is the co founder of Aclaris Therapeutics, Inc. and served as its Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary since its inception in 2012 until her retirement in January 2022. In addition, Ms. Ali Jackson co founded and successfully transitioned several specialty pharmaceutical and biopharmaceutical companies through multi million dollar acquisitions by global life sciences companies. In 2011, Ms. Ali Jackson also co founded NeXeption, Inc., a biopharmaceutical assets management company and was legal counsel for the company and its affiliated companies from 2011 until 2020. She has served as legal counsel and as a licensing business executive for a number of life sciences companies, including Merck & Co. Inc. and Dr. Reddy's Laboratories Ltd. Ms. Ali Jackson currently serves on the board of directors, audit, finance and compensation committees for Rigel Pharmaceuticals, Inc., a publicly traded biotechnology company. She has also served on several nonprofit boards and currently serves on the board of trustees of Princeton University and as the Chair of the East Bradford Township Zoning Hearing Board. Ms. Ali Jackson received her J.D. from Harvard Law School and Bachelor of Arts in politics from Princeton University.- Kamil Ali Jackson联合创立了公司并于2012年7月公司成立起担任法律总监和助理秘书。另外，2011年5月Ali-Jackson女士担任NeXeption股份有限公司（NeXeption, Inc.）的法律总监（2014年1月）。2011年5月-2013年9月Ali-Jackson女士担任Ceptaris Therapeutics股份有限公司（Ceptaris Therapeutics, Inc.，一家生物技术公司）法律总监、首席合规官和秘书。2010年10月-2011年9月她是一家私人特别制药公司的顾问。2006-2010年5月她担任Ception Therapeutics股份有限公司（Ception Therapeutics, Inc.，一家商务技术公司，被Cephalon股份有限公司（Cephalon, Inc.）收购）总法律顾问和公司秘书。先前，Ali-Jackson女士担任许多制药公司的法律顾问和特许业务执行，包括Merck & Co.股份有限公司（Merck & Co., Inc.）、Dr. Reddy's Laboratories股份有限公司（Dr. Reddy's Laboratories Inc.）和Endo Pharmaceuticals股份有限公司（Endo Pharmaceuticals, Inc）。Ali-Jackson女士拥有哈佛法学院（Harvard Law School）法律博士学位和普林斯顿大学（Princeton University）政治学士学位。
- Kamil Ali Jackson has served on the Board since February 2020. Ms. Ali Jackson has four decades of life sciences industry experience with public and private specialty pharmaceutical, biotech, and biopharmaceutical companies to PDS Biotech. Ms. Ali Jackson has extensive domestic and international experience with strategic alliances, drug development and commercialization collaborations, and M & A transactions. Ms. Ali Jackson is the co founder of Aclaris Therapeutics, Inc. and served as its Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary since its inception in 2012 until her retirement in January 2022. In addition, Ms. Ali Jackson co founded and successfully transitioned several specialty pharmaceutical and biopharmaceutical companies through multi million dollar acquisitions by global life sciences companies. In 2011, Ms. Ali Jackson also co founded NeXeption, Inc., a biopharmaceutical assets management company and was legal counsel for the company and its affiliated companies from 2011 until 2020. She has served as legal counsel and as a licensing business executive for a number of life sciences companies, including Merck & Co. Inc. and Dr. Reddy's Laboratories Ltd. Ms. Ali Jackson currently serves on the board of directors, audit, finance and compensation committees for Rigel Pharmaceuticals, Inc., a publicly traded biotechnology company. She has also served on several nonprofit boards and currently serves on the board of trustees of Princeton University and as the Chair of the East Bradford Township Zoning Hearing Board. Ms. Ali Jackson received her J.D. from Harvard Law School and Bachelor of Arts in politics from Princeton University.
- Frank Ruffo
Frank Ruffo联合创立了公司并于2012年7月公司成立起担任财务总监和秘书。Ruffo先生也兼职担任VenatoRx Pharmaceuticals股份有限公司（VenatoRx Pharmaceuticals Inc.，一家制药公司）的财务总监（2011年10月-2014年11月），也是BioLeap股份有限公司（BioLeap, Inc.）的财务总监（2010年1月-2013年1月）。在加入公司之前，Ruffo先生联合创立了Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.）的财务总监（2009-2011年7月被Allergan股份有限公司（Allergan, Inc.）收购）。在加入Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.）之前（1996-2008年），他担任CollaGenex Pharmaceuticals股份有限公司（CollaGenex Pharmaceuticals, Inc.）的财务副总裁和财务总监。他是前任注册会计师（非执业，2008年）。他拥有拉萨尔大学（LaSalle University）会计学士学位。
Frank Ruffo co-founded our company and has served as our Chief Financial Officer since our inception in July 2012. From January 2014 to December 2015 Mr. Ruffo served part-time as a financial consultant at Ralexar Therapeutics, Inc., a specialty dermatology company. Mr. Ruffo also served part-time as the Chief Financial Officer of VenatoRx Pharmaceuticals Inc., a pharmaceutical company, from October 2011 to November 2014 and the Chief Financial Officer of BioLeap, Inc. from January 2010 to January 2013. Prior to joining our company, Mr. Ruffo co-founded and served as Chief Financial Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Prior to joining Vicept Therapeutics, Inc., from 1996 to 2008 Mr. Ruffo served as the Vice President, Finance and Controller of CollaGenex Pharmaceuticals, Inc. He is a certified public accountant in Pennsylvania inactive since 2008. Mr. Ruffo received his B.S. degree in Accounting from LaSalle University.- Frank Ruffo联合创立了公司并于2012年7月公司成立起担任财务总监和秘书。Ruffo先生也兼职担任VenatoRx Pharmaceuticals股份有限公司（VenatoRx Pharmaceuticals Inc.，一家制药公司）的财务总监（2011年10月-2014年11月），也是BioLeap股份有限公司（BioLeap, Inc.）的财务总监（2010年1月-2013年1月）。在加入公司之前，Ruffo先生联合创立了Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.）的财务总监（2009-2011年7月被Allergan股份有限公司（Allergan, Inc.）收购）。在加入Vicept Therapeutics股份有限公司（Vicept Therapeutics, Inc.）之前（1996-2008年），他担任CollaGenex Pharmaceuticals股份有限公司（CollaGenex Pharmaceuticals, Inc.）的财务副总裁和财务总监。他是前任注册会计师（非执业，2008年）。他拥有拉萨尔大学（LaSalle University）会计学士学位。
- Frank Ruffo co-founded our company and has served as our Chief Financial Officer since our inception in July 2012. From January 2014 to December 2015 Mr. Ruffo served part-time as a financial consultant at Ralexar Therapeutics, Inc., a specialty dermatology company. Mr. Ruffo also served part-time as the Chief Financial Officer of VenatoRx Pharmaceuticals Inc., a pharmaceutical company, from October 2011 to November 2014 and the Chief Financial Officer of BioLeap, Inc. from January 2010 to January 2013. Prior to joining our company, Mr. Ruffo co-founded and served as Chief Financial Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Prior to joining Vicept Therapeutics, Inc., from 1996 to 2008 Mr. Ruffo served as the Vice President, Finance and Controller of CollaGenex Pharmaceuticals, Inc. He is a certified public accountant in Pennsylvania inactive since 2008. Mr. Ruffo received his B.S. degree in Accounting from LaSalle University.